Dry powder inhaler frees one of poor inhalation techniques

Dry powder inhaler (DPI) is a modern device that is designed using the latest biotechnology so that it facilitates the delivery of medicines directly in the lungs to relieve one from various respiratory diseases like bronchitis, asthma, emphysema, and CODP. This latest treatment device is also used for the treatment of diabetes mellitus. 

DPI requires a procedure that gives the right measure dose of the medicine that has to be used for the patient. There are two ways of taking the medication, one way involves manual loading of the capsule and the other way involves a proprietary form from the inside of the inhaler.

The ideal way to use this is to out the inhaler mouthpiece in the mouth and then followed up by taking a deep inhalation holding the breath for 5 to 10 seconds. In this form of treatment there are a variety of devices available but the effect will be delivered from using the latest and the most approved devices for the same.

SAVA Global, a leading pharma manufacturer in India manufactures the most updated DPI. With its analytical development, formulation development and regulatory affairs along with proper strategy for logistics and distribution. SAVA ensures that it does provide the optimum healthcare service and products to its global customers.  

Among various dry powder inhaler manufacturers in India, SAVA is emerging as a strong player. The device that it manufactures facilitates proper air flow as it directly reaches the lungs. This makes it more effective and since SAVA Global uses the latest technology in manufacturing the same, the effect is more. No wonder DPI manufactured by it is the most recommended by medical practitioners all over the globe.

This top pharma company in India is self-possessed to meet global market volatility and competent enough for larger business profits in the forthcoming years not only in the DPI but also in providing other healthcare products and services.  

Sava Global excels in being the leading pharma company in India

Sava Global, esteemed in 2003 is one of the fastest developing pharmaceutical organizations from India. Its core aim is to provide consumer health care for the betterment of the society as a whole. It provides pharmaceutical drugs at wholesale rates and also excels in services like contract research & contract manufacturing thus enhancing global consumer care by making a constant effort to make it better and better.

In recent years, India has become the most preferred pharmaceutical hub owing to expertise knowledge and low cost labor available in this nation. SAVA Global with its state of the art facilities, unmatched quality control, progressive research expertise, highly qualified team of research and development scientists, has emerged as an outstanding outsourcing hub for contract research and contract manufacturing.

This pharma manufacturer in India has its units at two places in India, Surendranagar ( Gujarat) and Bangalore (Karnataka). These manufacturing facilities are specialized facilities owing to which they are highly accredited with WHO-GMP, Kenya PPB, Nigeria, Iran NSD, Russia FDA, ISO 22000:2005, ISO 9001:2000, NOP Organic, USDA, Halal and Koshar.

Sava with its top class infrastructure specializes in :

• Literature search & Primary Patent Evaluation
• Product  and Analytical Development Report
• Prototype Development of Dosage Form
• Scale-up & Process Optimization & Process Validation
• Technology Transfer
• Packaging Development
• Commercial custom manufacturing
• Dossier Documentation in CTD Format 

Sava’s global presence in more than 35 countries is marked with very good network of marketing and distribution. These include hiring skilled resources that are available in the domestic scenario; stimulating competition by developing alternate source of vendor and suppliers, reducing elongated lead times by increasing the total supply capacity, providing backup for the risk of port shutdowns, and finding solutions to resolve the hindrance of monitoring the quality of product.

Its wide spectrum of business in healthcare includes OTC, Biopharmaceutical in finished dosage form, phyto-medicines, API & intermediates have made it the leading Indian pharma company and also the wholesale pharmaceutical drug supplier from India.

Sava is well poised to meet sudden or emerging market volatility and garner larger  business profits in the coming years from its burgeoning exports to the target countries including Russia, Singapore, Kenya , Europe etc.

Indian pharmaceutical companies will experience a windfall due to falling Rupee & Obamacare

Contradictory to some industries the rupee depreciation is a much delight to the pharmaceutical industry In India. This is because the export oriented Indian pharmaceutical firms will get more rupees in return of every dollar that they earn.

However the Indian currency that has fallen 15% since May this year is expected to show losses as well as gain. The Indian pharma industry is moving towards Specialty generic drugs and this will lead to better price realization.

The president of United States Barack Obama’s healthcare plan known as Obamacare aims at making medical treatments affordable to every American. This puts the Indian pharma industry in a happy place as it sees a boost in its growth, especially for the Indian drug exporter.

This scope for growth also brings the demand for high quality due to the increasing number of  United States FDA audits although exports may be cheaper due to the decline of Indian rupee.

Every pharma manufacturing company in India including SAVA Global is well aware of this and is taking measures where there will be zero tolerance towards any such thing that is against the US FDA norms. Drug makers are trying hard to attain a balance between exposures and hedge by adopting as well as in the building calibrated approach. 

As per the current status, pharmaceutical drugs exporter in India exports to more than 220 countries in the world which includes Russia, Singapore, Kenya and Brazil. 

As per expert analysis generics will continue dominating the market while the patent protected products will have a share of 10% till 2015.

It is expected that that the Indian pharma industry as well as Indian pharma exporter will experience a profitable scenario in their growth in the coming years.

Sava is well poised to meet this market volatility and garner larger  business profits in the coming years from its burgeoning exports to the target countries including Russia, Singapore, Kenya , Europe etc.